WESTMINSTER, Colo., November 18, 2025--(BUSINESS WIRE)--TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for ...

DENVER, June 04, 2025--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our ...

DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative ...

CEO Mary Szela reported strong third quarter results, highlighting revenue of $11.6 million, a 57% increase year-over-year and 3% sequential growth. She noted continued expansion of the TriNav ...

TriSalus Life Sciences Inc. (Nasdaq: TLSI), a Westminster-based oncology company, recorded a 57% increase in revenue for the third quarter ended Sept. 30, but the company also reported a higher net ...

(RTTNews) - TriSalus Life Sciences, Inc. (TLSI) has unveiled the TriNav FLX Infusion System, a new addition to its TriNav portfolio. The latest system enhances trackability and flexibility, allowing ...

TriSalus’ ongoing Phase 1 Pressure-Enabled Regional Immuno-Oncology (PERIO-01) (NCT04935229) clinical study for uveal melanoma with liver metastases (UMLM) is studying an investigational class C ...

TriSalus Life Sciences (TLSI) has announced a strategic partnership with Geo-Med to expand availability of the TriNav Infusion System to U.S. Department of Veterans Affairs medical centers nationwide.

“This study further validates the potential of TriNav using the PEDD approach to transform the treatment of liver tumors,” said Bryan F. Cox, Ph.D., Chief of Research for ...

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus ...

DENVER--(BUSINESS WIRE)--TriSalus TM Life Sciences (“TriSalus”), a company committed to transforming outcomes for patients with solid tumors, today announced the launch of its TriNav™ Infusion System ...

TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the ...